Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOP-3
- Development stage
- Preclinical
- Lead developer
- Imagine Pharma
- Modality
- Peptides
- Administration
- Topical
01
Overview
TOP-3 is a topical polypeptide therapeutic being developed by Imagine Pharma for the treatment of second-degree burns. It is based on the company's proprietary IMG-1 polypeptide platform, which is designed to promote tissue regeneration and wound healing. TOP-3 is specifically formulated for topical administration to burn sites to accelerate recovery and improve healing outcomes. The drug is part of Imagine Pharma's 'TOP' (Topical) therapeutic platform, which leverages the IMG-1 polypeptide for various wound-healing applications, including skin grafts and diabetic wounds.
- Other names
- burns TOP-3IMG-1 polypeptideIMG1 polypeptideIMG 1 polypeptide
02
Targets
IMG-1 (IMG-1 polypeptide)
Beyond the preview
Go deeper on TOP-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TOP-3.